Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?

被引：107

作者：

Asad, Juhi ^{[1
,2
]}

Jacobson, Allyson F. ^{[1
,2
]}

Estabrook, Alison ^{[1
]}

Smith, Sharon Rosenbaum ^{[1
]}

Boolbol, Susan K. ^{[2
]}

Feldman, Sheldon M. ^{[2
]}

Osborne, Michael P. ^{[2
]}

Boachie-Adjei, Kwadwo ^{[3
]}

Twardzik, Wendy ^{[1
]}

Tartter, Paul I. ^{[1
]}

机构：

[1] St Lukes Roosevelt Hosp, Div Breast Surg, New York, NY USA

[2] Beth Israel Deaconess Med Ctr, Div Breast Surg, New York, NY 10003 USA

[3] Beth Israel Deaconess Med Ctr, Div Surg Oncol, New York, NY 10003 USA

来源：

AMERICAN JOURNAL OF SURGERY | 2008年 / 196卷 / 04期

关键词：

Assay; 21-gene; Breast cancer; Management; Recurrence score;

D O I：

10.1016/j.amjsurg.2008.06.021

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

BACKGROUND: Oncotype DX is a 21-gene assay that calculates a risk of distant recurrence in women with estrogen-receptor-positive, lymph node-negative breast cancer. The purpose of this study was to determine whether the results of Oncotype DX influence the decision to administer chemotherapy. METHODS: A retrospective study was performed on 85 consecutive patients with estrogen-receptor-positive, lymph node-negative breast cancer who had an Oncotype DX recurrence score (RS) obtained. Tumor size, tumor grade, and treatment were then compared within each risk category. Statistical analysis was performed using STATA software. RESULTS: Tumors that were high grade and Her-2/neu positive more frequently had a high RS. Treatment was changed as a result of Oncotype DX in 44% of patients. CONCLUSIONS: Oncotype DX RS is significantly related to tumor grade and Her2/neu Status. In this Study. the treatment of 44% of patients was altered as a consequence of Oncotype DX RS. (C) 2008 Elsevier Inc. All rights reserved.

引用

页码：527 / 529

页数：3

共 6 条

[1]

ERB C, 2007, 2007 SAN ANT BREAST

[2] Treatment of lymph-node-negative, oestrogen-recept-postive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials [J].

Fisher, B ;

Jeong, JH ;

Bryant, J ;

Anderson, S ;

Dignam, J ;

Fisher, ER ;

Wolmark, N .

LANCET, 2004, 364 (9437) :858-868

[3]

Lo SS, 2007, J CLIN ONCOL, V25

[4] A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer [J].

Paik, S ;

Shak, S ;

Tang, G ;

Kim, C ;

Baker, J ;

Cronin, M ;

Baehner, FL ;

Walker, MG ;

Watson, D ;

Park, T ;

Hiller, W ;

Fisher, ER ;

Wickerham, DL ;

Bryant, J ;

Wolmark, N .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (27) :2817-2826

[5] Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer [J].

Paik, Soonmyung ;

Tang, Gong ;

Shak, Steven ;

Kim, Chungyeul ;

Baker, Joffre ;

Kim, Wanseop ;

Cronin, Maureen ;

Baehner, Frederick L. ;

Watson, Drew ;

Bryant, John ;

Costantino, Joseph P. ;

Geyer, Charles E., Jr. ;

Wickerham, D. Lawrence ;

Wolmark, Norman .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (23) :3726-3734

[6] Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients [J].

Wolf, Ido ;

Ben-Baruch, Noa ;

Shapira-Frommer, Ronnie ;

Rizel, Shulamit ;

Goldberg, Hadassa ;

Yaal-Hahoshen, Neora ;

Klein, Baruch ;

Geffen, David B. ;

Kaufman, Bella .

CANCER, 2008, 112 (04) :731-736

← 1 →